Summary
This German study aimed to evaluate the efficacy of a supplement containing 600 mg of magnesium, 400 mg of vitamin B2, and 150 mg of coenzyme Q10 as prophylactic treatment for migraine. 130 adults aged 18 to 65 years with 3 or more migraine attacks per month were divided into a supplementation group or a placebo group. The supplementation period lasted 3 months, following 4 weeks without prophylactic treatment. Among others, days with migraine, migraine pain, and disease burden were assessed before and after the supplementation period. The results showed a significantly reduced intensity of migraine pain and a reduced burden of disease compared to patients in the placebo group, indicating that treatment with this micronutrient supplement has beneficial effects in migraine patients. Further details can be found in the study.
References
Gaul et al.